{{Rsnum
|rsid=2298967
|Gene=HTT
|Chromosome=4
|position=3184020
|Orientation=plus
|GMAF=0.2626
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=HTT
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 7.8 | 37.5 | 54.7
| HCB | 10.0 | 42.5 | 47.5
| JPT | 7.0 | 51.2 | 41.9
| YRI | 0.0 | 1.6 | 98.4
| ASW | 0.0 | 0.0 | 0.0
| CHB | 10.0 | 42.5 | 47.5
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2298967
|Name_s=
|Gene_s=HTT
|Feature=
|Evidence=PubMed ID:19249009
|Annotation=This SNP is part of a haplogroup found to be associated with CAG repeat number expansion in Huntington disease (36 or more CAG repeats) in Europeans and also with intermediate expansion(27-35 repeats) in unaffected individuals(Europeans). This SNP itself was significantly associated(p < 0.0023) with the expansion.
|Drugs=
|Drug Classes=
|Diseases=Huntington Disease
|Curation Level=Curated
|PharmGKB Accession ID=PA164918149
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2298967
|overall_frequency_n=34
|overall_frequency_d=128
|overall_frequency=0.265625
|n_genomes=21
|n_genomes_annotated=0
|n_haplomes=25
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}